South China Morning Post

AstraZeneca, Merck, Novo deals boost Chinese biotech as global interest grows

Shares of Akeso surged after British drug maker AstraZeneca moved to advance the Chinese biotech firm’s flagship cancer drug, while a new deal from US giant Merck further underscored the sector’s global momentum amid easing fears of US curbs. AstraZeneca on Tuesday announced a US$2 billion equity investment in Florida-headquartered Summit Therapeutics, which holds the exclusive rights to develop and commercialise Akeso’s immunotherapy drug ivonescimab outside China. Summit and AstraZeneca would.

作者 South China Morning Post

1 分钟阅读
AstraZeneca, Merck, Novo deals boost Chinese biotech as global interest grows
AstraZeneca, Merck, Novo deals boost Chinese biotech as global interest grows

有活动行业的新闻要分享吗?

提交新闻稿或信息,触达数千名活动行业专业人士。

联系我们→

更多Startups & Entrepreneurship相关内容

相关洞察